Regulatory Jobs

ICH Q13 Puts a Regulatory Framework Around Continuous Manufacturing for the First Time

ICH Q13 gives regulators and manufacturers a shared definition of a batch, a control strategy and a validation approach for continuous drug manufacturing.

Connor Griggs

Connor GriggsMSRACQA

Founder & Editor-in-Chief

7 min read

Introduction

Traditional pharmaceutical manufacturing moves in discrete steps: a batch of material is made, tested, held, and released before the next stage begins. Continuous manufacturing collapses those steps into a single, integrated process where material flows through the line without stopping between unit operations. Companies have been experimenting with it for over a decade, drawn by the promise of smaller footprints, faster changeovers and tighter real-time control. What they lacked for most of that time was a harmonized regulatory framework that defined, in terms regulators across regions would accept, what counts as a batch in a process that never technically stops. ICH Q13, finalized in 2022, is that framework, and it is quietly reshaping how CMC and quality teams think about process design, control strategy and validation, replacing a decade of company-by-company negotiation with a reference point every program can design against from the outset.

What Continuous Manufacturing Changes on the Floor

In a batch process, material sits in discrete lots that can be sampled, tested and held at defined points, giving a company a natural place to catch a problem before it propagates. In a continuous process, raw materials are fed in and finished product comes out on an ongoing basis, often with in-line or at-line process analytical technology monitoring critical quality attributes in real time rather than through end-of-batch testing. That shift enables real-time release testing in some cases, where a product's quality is demonstrated through validated in-process measurements and process data rather than a separate finished-product test, but it also removes some of the natural checkpoints a conventional batch process offers. A control strategy for a continuous process has to compensate for that by building in material traceability, diversion capability for out-of-specification material, and a much tighter relationship between process parameters and quality outcomes than most batch processes require.

What ICH Q13 Actually Covers

The guideline applies to continuous manufacturing of both drug substances and drug products, across small molecules and some biotechnological and biological entities, and it addresses the questions that had been left to case-by-case negotiation between individual companies and individual regulators before harmonization. It defines how a batch should be specified for a continuous process, since the traditional definition tied to a single, discrete production run does not map cleanly onto an operation that can run for days. It describes expectations for control strategy, including the role of process analytical technology and real-time release testing where a company chooses to use them. It also addresses the handling of transitional dynamics, meaning the start-up and shutdown periods of a continuous run where process conditions have not yet reached steady state, and how material produced during those periods should be assessed and, where appropriate, diverted from the batch intended for release.

The guideline also speaks to process validation in a way that departs from how most CMC professionals learned it. Rather than validating a process through a fixed number of demonstration batches, as is common in batch manufacturing, ICH Q13 builds on the lifecycle approach already established in ICH Q8 through Q12, where ongoing process verification is used to confirm a continuous process remains in a state of control over an extended run. That matters practically because a continuous process can, in principle, run far longer than a conventional batch, and the guideline has to address how a company demonstrates sustained control over that duration rather than simply at a handful of sampled points.

Why a Dedicated Guideline Was Needed

Before ICH Q13, companies developing continuous processes often had to negotiate control strategy and validation expectations separately with each regulatory authority reviewing their submission, since existing ICH guidance on process validation and quality systems was written with batch manufacturing as the implicit model. That created real friction for companies running global development programs, because a control strategy acceptable to one agency was not guaranteed to satisfy another, and the absence of a shared definition of batch size and traceability for continuous processes made cross-regional comparability difficult to demonstrate. Harmonizing those expectations through ICH Q13 reduces that friction and gives companies a clearer target to design against from the start of development, rather than discovering regional gaps late in a filing.

Harmonization also matters for companies that did not design their process with any single region's regulators in the room. Mid-size and smaller biotechs, in particular, often lack the regulatory affairs bandwidth to run parallel informal discussions with multiple agencies at once, and a shared guideline gives them a reference point they can design against independently, then defend consistently across every market they eventually file in. That is a meaningful change from the earlier period, when continuous manufacturing programs were realistically only approachable by larger companies with the regulatory relationships and resources to negotiate region by region.

What This Means for CMC and Quality Hiring

Teams building or supporting continuous manufacturing processes increasingly need fluency in process analytical technology, including the statistical and software tools used to monitor a process in real time, alongside traditional pharmaceutical science training. CMC regulatory writers are being asked to describe control strategies and batch definitions for continuous processes in submissions, which requires understanding the process engineering well enough to translate it accurately rather than adapting batch-manufacturing language loosely. Quality professionals supporting these lines need comfort with statistical process control and a more continuous, data-driven approach to deviation management, since a transient excursion in a continuous process has to be evaluated against process dynamics rather than treated as an isolated batch event. Validation specialists are also seeing the lifecycle approach to process validation, already familiar from ICH Q8 through Q12, extended into a continuous-manufacturing context where the concept of ongoing process verification takes on a more literal, uninterrupted meaning.

Inspectors are developing a parallel set of expectations, and that is creating its own hiring pressure inside quality organizations. Auditing a continuous line well requires understanding how the control strategy, the process analytical technology and the diversion logic fit together as a system, rather than inspecting discrete process steps in isolation the way a batch-line audit typically proceeds. Companies running continuous lines increasingly want internal auditors and quality systems specialists who have actually worked with this kind of integrated control strategy before an external inspection happens, not people learning the logic for the first time alongside the inspector.

Where Continuous Manufacturing Is Showing Up First

Adoption has concentrated in oral solid dosage manufacturing, where several companies have already secured regulatory approvals for continuously manufactured products, and interest is extending into drug substance manufacturing and some biologics unit operations as the underlying technology matures. Generic manufacturers have also shown interest in continuous processes as a way to improve cost efficiency and reduce footprint, though the validation and regulatory investment required to convert an established batch process to continuous manufacturing is substantial enough that adoption has been gradual rather than sweeping. Companies building new manufacturing capacity, rather than converting existing lines, are generally in the best position to adopt continuous approaches from the start, since greenfield facility design avoids the added complexity of retrofitting continuous equipment into a plant built around batch logic.

Contract development and manufacturing organizations have also begun building out continuous manufacturing capacity specifically to offer it as a service, which lowers the barrier for smaller sponsors who want the efficiency benefits without building and validating a continuous line themselves. That arrangement shifts some of the process analytical technology and control strategy expertise into the CDMO's own organization, which means sponsors evaluating a CDMO for a continuous program need to assess that partner's regulatory track record with continuous submissions specifically, not just its general manufacturing quality history.

What to Watch

ICH Q13 is a harmonized framework, not a finished rulebook, and individual regions are still working through how their existing inspection and submission practices accommodate it in practice. Companies should expect inspection expectations for continuous manufacturing facilities to keep evolving as regulators gain more hands-on experience auditing these lines, and submission reviewers to continue refining how they evaluate control strategies that lean heavily on process analytical technology and real-time release testing. For CMC and quality professionals, staying current on regional implementation guidance, rather than assuming ICH Q13 alone fully answers every practical question, remains the safer approach while the framework matures. Professionals who make a point of reading agency Q&A documents and pilot program updates as they are published, rather than waiting for a settled final position, tend to have a real advantage when their own company's continuous manufacturing program eventually reaches submission.

Conclusion

ICH Q13 does not make continuous manufacturing easy, but it does make it navigable, replacing a patchwork of regional negotiation with a shared vocabulary for batch definition, control strategy and validation. For regulatory, quality and CMC professionals, the guideline marks continuous manufacturing's shift from an experimental niche to a standard option in process design, and the skills it rewards, process analytical technology fluency, statistical process understanding and precise technical writing, are becoming a genuine differentiator in manufacturing-focused hiring, one that is likely to keep paying off as more programs move from pilot projects to filed, commercial-scale processes.

Regulatory & Quality. REWIRED.

New roles. Real pay. Your next move.

  • Hand-picked roles, every week.
  • The newest company pages.
  • One article worth your time.
Get the Weekly

Free. Thursday mornings. One-click unsubscribe.

Connor GriggsConnor Griggs

About the author

Connor GriggsMSRA, CQA

Founder & Editor-in-Chief

Connor began his career as a regulatory analyst at the FDA and has spent 13 years in medical device regulatory affairs and quality.

Find your next regulatory or quality role

Every role on Regulatory Jobs is in regulatory, quality or clinical, in pharma, biotech or medical devices. Set an alert and the next one reaches you the day it posts.

Next in News & UpdatesWhat FDA's QMSR Means for Regulatory and Quality Careers in Medical Devices